Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
TNYA | US
0.03
3.67%
Healthcare
Biotechnology
30/06/2024
13/04/2026
0.72
0.69
0.74
0.68
Tenaya Therapeutics Inc. a biotechnology company discovers develops and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration gene therapy and precision medicine platforms. The company is developing TN-201 a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy; TN-301 a small molecule for heart failure with preserved ejection fraction; and TN-401 a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy. It also develops an adeno-associated virus-based gene therapy designed to deliver the dwarf open reading frame gene in the heart for dilated cardiomyopathy; and reprogramming program for cardiac regeneration to replace heart cells lost in patients experiencing heart failure due to prior myocardial infarction. The company was incorporated in 2016 and is headquartered in South San Francisco California.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
98.3%1 month
78.4%3 months
125.1%6 months
121.5%-
-
1.27
0.12
0.10
-0.67
-
-
-118.31M
73.07M
73.07M
-
-
-
-
-74.54
12.39
9.23
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
0.16
Range1M
0.29
Range3M
0.50
Rel. volume
0.87
Price X volume
1.85M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Pliant Therapeutics Inc. | PLRX | Biotechnology | 1.3 | 79.04M | 1.56% | n/a | 15.34% |
| iShares MSCI Brazil ETF USD Acc | CSBR | Biotechnology | 5.74 | 78.03M | -0.17% | n/a | -2140.66% |
| Cassava Sciences Inc | SAVA | Biotechnology | 1.62 | 77.72M | -1.22% | n/a | 0.00% |
| CRDF | CRDF | Biotechnology | 1.59 | 74.01M | 0.63% | n/a | 3.52% |
| Fortress Biotech Inc | FBIOP | Biotechnology | 13.6887 | 73.48M | 0.06% | n/a | 494.61% |
| XBiotech Inc | XBIT | Biotechnology | 2.41 | 73.42M | 3.43% | n/a | 5.08% |
| MediciNova Inc | MNOV | Biotechnology | 1.44 | 70.63M | -3.36% | n/a | 0.86% |
| BeyondSpring Inc | BYSI | Biotechnology | 1.7501 | 70.53M | 0.58% | n/a | -14.90% |
| PMV Pharmaceuticals Inc | PMVP | Biotechnology | 1.35 | 69.55M | 2.27% | n/a | 6.06% |
| Biomea Fusion Inc. Common Stock | BMEA | Biotechnology | 1.88 | 68.08M | 0.53% | n/a | 9.95% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Saga Communications Inc | SGA | Broadcasting - Radio | 11.6936 | 73.22M | -0.73% | 14.48 | 7.10% |
| ILAG | ILAG | Building Products & Equipment | 3.56 | 64.29M | 0.28% | n/a | 5.48% |
| Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 10.4 | 15.84M | -11.56% | n/a | 204.46% |
| Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.8799 | 12.86M | -18.53% | 0.03 | 16.03% |
| REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 0.6 | 11.59M | -0.17% | n/a | 58.43% |
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.33 | 3.40M | -0.75% | n/a | 17.32% |
| Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.2276 | 2.17M | -10.25% | n/a | 19.98% |
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 2.07 | 1.14M | -0.96% | n/a | 0.00% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.67 | 0.53 | Cheaper |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 1.27 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 125.09 | 72.80 | Riskier |
| Debt to Equity | 0.12 | -1.23 | Expensive |
| Debt to Assets | 0.10 | 0.25 | Cheaper |
| Market Cap | 73.07M | 3.66B | Emerging |